Stockscreener 앱 받기
1.25
1.57%
-0.02
시간 외 거래:
1.24
-0.01
-0.80%
Sonnet Biotherapeutics Holdings Inc 주식(SONN)의 최신 뉴스
Sonnet BioTherapeutics Says Ovarian Cancer Drug Showed 'Positive' Safety Data in Phase 1b/2a Trial; Shares Up - MarketScreener
Sonnet says SON-1010 demonstrates ‘strong safety profile’ in atezolizumab combo - TipRanks
Sonnet BioTherapeutics advances in cancer trial - Investing.com
Sonnet'S Son-1010 Demonstrates A Strong Safety Profile In Combination With Atezolizumab For Treatment Of Platinum-Resistant Ovarian Cancer - MarketScreener
Sonnet’s SON-1010 Demonstrates a Strong Safety Profile in Combination with Atezolizumab for Treatment of Platinum-Resistant Ovarian Cancer, Including a Partial Response at the Highest Dose - GlobeNewswire
Sonnet Announces Release of Corporate Update Video - GlobeNewswire
Sonnet BioTherapeutics appoints interim CEO and new president By Investing.com - Investing.com South Africa
Sonnet BioTherapeutics appoints interim CEO and new president - Investing.com
Pilot Killed In Franklin Twp Plane Crash Was CEO Of Cancer-Focused Biotech Company - dailyvoice.com
Sonnet Announces the Passing of Founder and CEO Pankaj Mohan, Ph.D. - citybiz
Sonnet BioTherapeutics appoints interim CEO after founder’s death - Investing.com
Sonnet Announces The Passing Of Founder And CEO Pankaj Mohan - MarketScreener
Leadership Change at Sonnet BioTherapeutics: Founder Passes, New Executive Team Steps In - Stock Titan
Chardan Capital Reaffirms Buy Rating for Sonnet BioTherapeutics (NASDAQ:SONN) - Defense World
Sonnet BioTherapeutics’ (SONN) Buy Rating Reaffirmed at Chardan Capital - The AM Reporter
SONN stock touches 52-week low at $1.28 amid market challenges - Investing.com Australia
Sonnet BioTherapeutics Successfully Completes First Safety - GlobeNewswire
Sonnet BioTherapeutics Successfully Completes First Safety Review Of SON-1010 In Combination With Trabectedin In Certain Sarcomas - MarketScreener
Clinical Trial Success: New Cancer Drug Combo Shows 83% Disease Control in Sarcoma Patients - Stock Titan
Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) Short Interest Up 16.4% in February - Defense World
Sonnet BioTherapeutics secures new IL-18 patent - Investing.com
Sonnet BioTherapeutics secures new IL-18 patent By Investing.com - Investing.com South Africa
Sonnet BioTherapeutics Secures Second Patent for IL-18 Variant - TipRanks
Sonnet BioTherapeutics Receives Notice of Allowance for - GlobeNewswire
Major Patent Win: Sonnet's Revolutionary IL-18 Cancer Treatment Shows Superior Binding Properties - StockTitan
Sonnet BioTherapeutics Receives Notice of Allowance for U.S. Patent Covering Composition of Matter of Specific Amino Acid Substitutions of its IL-18 Binding Protein Resistant Variant Protein - The Manila Times
Sonnet BioTherapeutics Holdings, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference - GlobeNewswire
Sonnet BioTherapeutics Holdings, Inc. Announces Availability of On-Demand Video Webcast Following Virtual Investor "Top 5 for ‘25" Conference - Nasdaq
Sonnet Bio CEO Unveils 5 Game-Changing Developments Coming in 2025 - StockTitan
XRP Plunges as Recession Panic and Crypto Summit Fallout Slam Investors - The Globe and Mail
Sonnet BioTherapeutics Stock Price, Quotes and Forecasts - Benzinga
SONN stock touches 52-week low at $1.33 amid market challenges - Investing.com UK
Sonnet BioTherapeutics Provides Fiscal Year 2022 First Quarter Business and Earnings Update - ACCESS Newswire
Sonnet BioTherapeutics Highlights Promising SON-1010 Data - TipRanks
Sonnet BioTherapeutics Presents Compilation of Data Highlighting the Potential of SON-1010 as a Monotherapy or a Combination Therapy to Improve the Treatment of Solid Tumors - The Manila Times
Sonnet BioTherapeutics Presents Innovative FHAB® Platform Data at 2025 AACR:IO Conference - Nasdaq
Sonnet BioTherapeutics Presents Compilation of Data - GlobeNewswire
Can This Immunotherapy Beat Solid Tumors? Sonnet's SON-1010 Shows 48% Clinical Benefit - StockTitan
Sonnet BioTherapeutics Announces Availability of Proprietary ADC Platform for Drug Discovery Partnerships - The AM Reporter
Sonnet BioTherapeutics advances novel ADC platform By Investing.com - Investing.com Australia
Sonnet BioTherapeutics advances novel ADC platform - Investing.com
SONN stock touches 52-week low at $1.38 amid market challenges - Investing.com India
Sonnet Biotherapeutics' Proprietary ADC Platform Available For Drug Discovery Partnerships - Marketscreener.com
Sonnet BioTherapeutics Announces That Its Proprietary - GlobeNewswire
Sonnet BioTherapeutics Advances Antibody Drug Conjugate Platform - TipRanks
2 Hot Growth Stocks Poised for Gains of Up to 370%, According to Wall Street - The Globe and Mail
Can This New ADC Platform Challenge Established Cancer Drugs? Preclinical Data Shows Promise - StockTitan
3.01%
자본화:
|
볼륨(24시간):